Matej
Oresic
InFLAMES Flagship
Professor, Turku Bioscience Centre
Ph.D.
Areas of expertise
Systems biology
bioinformatics
metabolomics
lipidomics
biophysics
systems medicine
computational biology
Biography
Professor Matej Orešič holds a PhD in biophysics from Cornell University. He is Professor of Medical Sciences with Specialization in Systems Medicine at School of Medical Sciences (Örebro University, Sweden), Group Leader in Systems Medicine at the Turku Bioscience Centre (University of Turku, Finland), and Guest Professor at the Oil Crops Research Institute Chinese Academy of Agricultural Sciences (Wuhan, PR China). His main research areas are metabolomics applications in biomedical research and integrative bioinformatics. He is particularly interested in the identification of disease vulnerabilities associated with different metabolic phenotypes and the underlying mechanisms linking these vulnerabilities with the development of specific disorders or their co-morbidities, with specific focus on obesity and diabetes and their co-morbidities. Dr. Orešič has also initiated the popular MZmine open source project, leading to popular software for metabolomics data processing. Previosuly, Dr. Orešič was principal investigator at Steno Diabetes Center (Gentofte, Denmark), research professor at VTT Technical Research Centre of Finland (Espoo, Finland), head of computational biology and modeling at Beyond Genomics, Inc. (Waltham/MA) and bioinformatician at LION Bioscience Research in Cambridge/MA. In 2016, Dr. Oresic received the Lifetime Honorary Fellow award from the Metabolomics Society.
Research
Our main research area is systems medicine, particularly metabolomics applications in biomedical research and related integrative bioinformatics. Specifically, we am particularly interested in the identification of disease vulnerabilities associated with different metabolic phenotypes and the underlying mechanisms linking these vulnerabilities with the development of specific disorders or their co-morbidities. Such in depth understanding of the metabolic phenotypes in health and disease is crucial if one is to implement personalized medicine. Dr. Orešič initiated the popular MZmine open source project, leading to popular software for metabolomics data processing.
Main ongoing projects:
Strategic Research Agreement, Juvenile Diabetes Research Foundation (9/2016-9/2018): Metabolomic and Proteomic markers staging progression to type 1 diabetes in autoantibody positive children – PI
Strategic Research Agreement, Juvenile Diabetes Research Foundation (9/2016-9/2018): Mother-infant interactions in relation to potential biomarkers of beta-cell autoimmunity and type 1 diabetes – PI
Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (2012-2017) - PI
Strategic Research Agreement, Juvenile Diabetes Research Foundation (Integrative multi-omic study of early progression to type 1 diabetes; 2014-2017) - PI
pHealth Programme, multi-PI collaborative project, Academy of Finland (Personalised medicine to predict and prevent Type 1 Diabetes; 9/2015-8/2019) – Co-PI
EU H2020 EPoS (Elucidating Pathways of Steatohepatitis) - Workpackage leader
EU FP7 METSY (Integrated neuroimaging and metabolic platform for characterisation of early psychosis and prediction of patient outcomes) - Coordinator
Publications
Quantitative modelling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease (2022)
iScience
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance (2022)
JHEP Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Metabolomic and proteomic profiling in bipolar disorder patients revealed potential molecular signatures related to hemostasis (2022)
Metabolomics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Dysregulation of secondary bile acid metabolism precedes islet autoimmunity and type 1 diabetes (2022)
Cell Reports Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease (2022)
JHEP Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Permutation-based significance analysis reduces the type 1 error rate in bisulfite sequencing data analysis of human umbilical cord blood samples (2022)
Epigenetics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study (2022)
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))Umbilical cord blood DNA methylation in children who later develop type 1 diabetes (2022)
Diabetologia
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Analysis of the SYSDIET Healthy Nordic Diet randomized trial based on metabolic profiling reveal beneficial effects on glucose metabolism and blood lipids (2022)
Clinical Nutrition
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Correction: Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling (Journal of Proteome Research (2012) 11:2 (850-860) DOI: 10.1021/pr200685r) (2022)
Journal of Proteome Research
(O2 Muu julkaisu )